Autism, a spectrum disorder, manifests uniquely in individuals, but difficulties in social interactions and communication are common across cases. Early diagnosis is critical as autism begins in the prenatal stage, and the brain’s plasticity during the first few years makes it highly responsive to intervention. Despite the potential to diagnose autism by 18 months, the average diagnosis age in the U.S. is close to five years, with even later diagnoses in African-American children. Genetic factors set the stage for autism, but environmental interactions shape the brain’s development. Disrupted synaptic pruning in autism leads to atypical brain development, influenced by differences in attention patterns from infancy.
At Duke University, researchers aim to identify at-risk infants using biomarkers like gene expression, immune system changes, and brain activity patterns. They developed the Early Start Denver Model (ESDM), an intervention emphasizing social engagement and language development, which has shown significant behavioral and neural benefits, including a 17-point average IQ gain. ESDM has been adapted for global accessibility, training parents to deliver interventions, with promising outcomes in countries like China and South Africa.
Despite early intervention’s success, 25% of autistic individuals remain nonverbal. Duke is exploring molecular and cellular therapies to enhance neuroplasticity and improve outcomes for these individuals. One trial, in collaboration with Dr. Joanne Kurtzberg, investigates umbilical cord blood therapy, leveraging its stem cells to reduce neuroinflammation and promote functional brain connectivity. Preliminary trials show promising results for conditions like autism, cerebral palsy, and stroke, signaling hope for innovative therapeutic advancements.
